Bioage Labs Inc (BIOA)

$18.16 +0.17 (0.94%)
Market Cap 798.40M
Revenue (ttm) 9.00M
Net Income (ttm) -80.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -895.67%
Debt to Equity Ratio 0.01
Volume 507,477
Avg Vol 486,042
Day's Range N/A - N/A
Shares Out 44.38M
Stochastic %K 70%
Beta 0.99
Analysts Strong Sell
Price Target $53.33

Company Profile

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease,...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 510 806 1445
Address:
5885 Hollis Street, Suite 370, EmeryVille, United States
MarketBeat
MarketBeat May. 8 at 8:03 PM
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials $BIOA #BioAgeLabs #instantalerts #NASDAQ:BIOA
0 · Reply
focafoca99
focafoca99 May. 8 at 1:38 PM
$BIOA released its first-quarter 2026 financial results.
0 · Reply
bryyep649
bryyep649 May. 6 at 11:07 PM
$BIOA when I put bioage into grok it says it has a possible vaccine for hauntavirus. Maybe that’s why we saw the uptick today. Things that make you go hmmmmmm. Or it could be the Friday investor day
0 · Reply
ballerallday
ballerallday May. 6 at 7:22 PM
$BIOA Huge $475.9K call buying on the July 22.50s. 😲
0 · Reply
CrocksAndPonds
CrocksAndPonds May. 4 at 5:52 PM
$BIOA Nice price on options here, just bought a batch at 16.36 and wrote May 15 $17.50 calls at .55
1 · Reply
romanaround
romanaround Apr. 29 at 10:12 PM
$ALT $BIOA $TERN $VKTX gosh dang my apologies to tern and bioa they are on top kings
0 · Reply
skyrockets_Inc
skyrockets_Inc Apr. 21 at 5:08 PM
$VTGN Likely in coming weeks. They announced data as '1H 2026' instead of Q2. $BIOA announced the same thing '1H 2026' and just released their data today. I think we are due within weeks, possibly by end of April.
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 2:44 PM
$BIOA Pros: - best-in-class reduction of inflammation - oral - brain-penetrant (allows ophthalmolgy and CNS indications) - huge TAMs - last funding at $19.5 - runway through 2029 - NVO and LLY partnerships Cons - too early stage (unless it gets acquired...) with many unknowns
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 1:06 PM
$BIOA As clarified in the call headache was associated with lumbar punctures consucted in treatment arms for pk/pd studies
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 12:20 PM
$BIOA Targeting/potential in many large TAMs: - CVD disease - obesity - DME, GA Room for >1 players too
0 · Reply
Latest News on BIOA
BioAge Labs Transcript: Status update

May 8, 2026, 12:30 PM EDT - 3 days ago

BioAge Labs Transcript: Status update

BioAge Labs reports Q1 EPS (52c), consensus (63c)

2026-05-08T15:21:29.000Z - 3 days ago

BioAge Labs reports Q1 EPS (52c), consensus (63c)

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

May 8, 2026, 9:00 AM EDT - 3 days ago

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

May 4, 2026, 4:30 PM EDT - 7 days ago

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2

2026-04-21T12:30:33.000Z - 20 days ago

BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2

BioAge Labs Transcript: Study result

Apr 21, 2026, 8:00 AM EDT - 20 days ago

BioAge Labs Transcript: Study result

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

Apr 21, 2026, 7:00 AM EDT - 20 days ago

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

BioAge Labs Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 16, 2026, 3:00 PM EDT - 25 days ago

BioAge Labs Transcript: 25th Annual Needham Virtual Healthcare Conference

BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference

Apr 13, 2026, 4:30 PM EDT - 4 weeks ago

BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference

BioAge Labs initiated with a Buy at Needham

2026-03-27T10:27:07.000Z - 6 weeks ago

BioAge Labs initiated with a Buy at Needham

BioAge Labs files automatic mixed securities shelf

2026-03-24T20:25:15.000Z - 6 weeks ago

BioAge Labs files automatic mixed securities shelf

BioAge Labs price target raised to $52 from $15 at Citi

2026-03-10T10:41:09.000Z - 2 months ago

BioAge Labs price target raised to $52 from $15 at Citi

BioAge Labs Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 10:40 AM EST - 2 months ago

BioAge Labs Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

BioAge Labs initiated with an Outperform at Oppenheimer

2026-02-24T21:48:29.000Z - 2 months ago

BioAge Labs initiated with an Outperform at Oppenheimer

VTYX

BioAge Labs upgraded to Buy from Hold at Jefferies

2026-02-18T11:10:46.000Z - 2 months ago

BioAge Labs upgraded to Buy from Hold at Jefferies

BioAge Labs price target raised to $23 from $12 at Morgan Stanley

2026-02-04T13:36:59.000Z - 3 months ago

BioAge Labs price target raised to $23 from $12 at Morgan Stanley

BioAge Labs initiated with an Overweight at Piper Sandler

2026-01-27T10:15:29.000Z - 3 months ago

BioAge Labs initiated with an Overweight at Piper Sandler

BioAge Announces Pricing of Upsized $115.0 Million Public Offering

Jan 21, 2026, 10:30 PM EST - 3 months ago

BioAge Announces Pricing of Upsized $115.0 Million Public Offering

BioAge Labs announces $75M common stock offering

2026-01-20T21:11:22.000Z - 3 months ago

BioAge Labs announces $75M common stock offering

BioAge Announces Proposed Public Offering

Jan 20, 2026, 4:01 PM EST - 3 months ago

BioAge Announces Proposed Public Offering

BioAge Labs management to meet with Piper Sandler

2026-01-20T19:55:19.000Z - 3 months ago

BioAge Labs management to meet with Piper Sandler

BioAge Labs announces expansion of its BGE-102 development program

2026-01-20T14:16:25.000Z - 3 months ago

BioAge Labs announces expansion of its BGE-102 development program

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

Jan 20, 2026, 9:00 AM EST - 3 months ago

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

BioAge Labs announces additional interim data from Phase 1 trial of BGE-102

2026-01-12T14:17:28.000Z - 4 months ago

BioAge Labs announces additional interim data from Phase 1 trial of BGE-102

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk

Jan 12, 2026, 9:00 AM EST - 4 months ago

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk

BioAge Labs upgraded to Equal Weight from Underweight at Morgan Stanley

2025-12-05T18:30:16.000Z - 5 months ago

BioAge Labs upgraded to Equal Weight from Underweight at Morgan Stanley

BioAge Labs Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 4, 2025, 1:30 PM EST - 5 months ago

BioAge Labs Transcript: Piper Sandler 37th Annual Healthcare Conference

BioAge Labs announces interim Phase 1 data for BGE-102

2025-12-04T14:05:55.000Z - 5 months ago

BioAge Labs announces interim Phase 1 data for BGE-102

BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

Dec 4, 2025, 9:00 AM EST - 5 months ago

BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 4:30 PM EST - 5 months ago

BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

BioAge Labs Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 7:30 AM EST - 6 months ago

BioAge Labs Transcript: Jefferies London Healthcare Conference 2025

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

Nov 7, 2025, 9:00 AM EST - 6 months ago

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

BioAge Labs price target raised to $15 from $10 at Citi

2025-10-29T11:27:21.000Z - 6 months ago

BioAge Labs price target raised to $15 from $10 at Citi

HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor

Sep 15, 2025, 9:30 AM EDT - 8 months ago

HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor

BioAge Labs Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 10:00 AM EDT - 8 months ago

BioAge Labs Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

BioAge Labs Transcript: Citi's Biopharma Back to School Conference

Sep 3, 2025, 3:15 PM EDT - 8 months ago

BioAge Labs Transcript: Citi's Biopharma Back to School Conference

BioAge Labs to Present at Upcoming Investor Conferences

Aug 20, 2025, 4:30 PM EDT - 9 months ago

BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

Aug 15, 2025, 9:00 AM EDT - 9 months ago

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 6, 2025, 4:30 PM EDT - 9 months ago

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Jun 21, 2025, 6:00 PM EDT - 11 months ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank

Jun 17, 2025, 9:00 AM EDT - 11 months ago

BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank

BioAge Labs Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 3:20 PM EDT - 1 year ago

BioAge Labs Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 4:30 PM EDT - 1 year ago

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

Mar 20, 2025, 4:30 PM EDT - 1 year ago

BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOA

Mar 10, 2025, 9:30 PM EDT - 1 year ago

Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOA

BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

Mar 10, 2025, 6:33 PM EDT - 1 year ago

BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

BIOA Deadline: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

Mar 5, 2025, 3:45 PM EST - 1 year ago

BIOA Deadline: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

BIOA REMINDER: BioAge Labs was Sued for Securities Violations; Investors are Alerted to Contact BFA Law before March 10 Deadline (NASDAQ:BIOA)

Mar 2, 2025, 7:23 AM EST - 1 year ago

BIOA REMINDER: BioAge Labs was Sued for Securities Violations; Investors are Alerted to Contact BFA Law before March 10 Deadline (NASDAQ:BIOA)

BIOA Deadline: BIOA Investors with Losses in Excess of $100K Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

Feb 28, 2025, 3:30 PM EST - 1 year ago

BIOA Deadline: BIOA Investors with Losses in Excess of $100K Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit

MarketBeat
MarketBeat May. 8 at 8:03 PM
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials $BIOA #BioAgeLabs #instantalerts #NASDAQ:BIOA
0 · Reply
focafoca99
focafoca99 May. 8 at 1:38 PM
$BIOA released its first-quarter 2026 financial results.
0 · Reply
bryyep649
bryyep649 May. 6 at 11:07 PM
$BIOA when I put bioage into grok it says it has a possible vaccine for hauntavirus. Maybe that’s why we saw the uptick today. Things that make you go hmmmmmm. Or it could be the Friday investor day
0 · Reply
ballerallday
ballerallday May. 6 at 7:22 PM
$BIOA Huge $475.9K call buying on the July 22.50s. 😲
0 · Reply
CrocksAndPonds
CrocksAndPonds May. 4 at 5:52 PM
$BIOA Nice price on options here, just bought a batch at 16.36 and wrote May 15 $17.50 calls at .55
1 · Reply
romanaround
romanaround Apr. 29 at 10:12 PM
$ALT $BIOA $TERN $VKTX gosh dang my apologies to tern and bioa they are on top kings
0 · Reply
skyrockets_Inc
skyrockets_Inc Apr. 21 at 5:08 PM
$VTGN Likely in coming weeks. They announced data as '1H 2026' instead of Q2. $BIOA announced the same thing '1H 2026' and just released their data today. I think we are due within weeks, possibly by end of April.
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 2:44 PM
$BIOA Pros: - best-in-class reduction of inflammation - oral - brain-penetrant (allows ophthalmolgy and CNS indications) - huge TAMs - last funding at $19.5 - runway through 2029 - NVO and LLY partnerships Cons - too early stage (unless it gets acquired...) with many unknowns
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 1:06 PM
$BIOA As clarified in the call headache was associated with lumbar punctures consucted in treatment arms for pk/pd studies
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 12:20 PM
$BIOA Targeting/potential in many large TAMs: - CVD disease - obesity - DME, GA Room for >1 players too
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Apr. 21 at 12:13 PM
$BIOA best hsCRP reduction + oral + brain-penetrant
0 · Reply
skyrockets_Inc
skyrockets_Inc Apr. 21 at 11:43 AM
$BIOA https://ir.bioagelabs.com/news-releases/news-release-details/bioage-reports-positive-phase-1-data-bge-102-novel-oral-nlrp3
0 · Reply
S2K_TP
S2K_TP Apr. 18 at 5:41 PM
$BIOA still watching this 20 break at some point
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 2 at 1:31 AM
$BIOA RSI: 43.08, MACD: -0.8938 Vol: 1.92, MA20: 18.86, MA50: 19.68 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 27 at 6:43 PM
$BIOA Share Price: $16.27 Contract Selected: Dec 18, 2026 $22.5 Calls Buy Zone: $0.85 – $1.05 Target Zone: $1.36 – $1.67 Potential Upside: 52% ROI Time to Expiration: 265 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
notreload_ai
notreload_ai Mar. 27 at 12:38 PM
Needham started coverage of $BIOA with a Buy rating and $50 price target. Analysts are bullish on lead asset BGE-102, an oral NLRP3 inhibitor for cardiovascular risk in obese patients. https://notreload.xyz/needham-initiates-buy-rating-on-bioage-labs/
0 · Reply
Steppinstone
Steppinstone Mar. 26 at 2:01 AM
$BIOA Full set of Phase 1 data including last obese cohort should be reported sometime within 90 days. Phase 2a trial is guided to initiate within 90 days in CV along with Phase 1/2 trial in DME and then GA. Remember Lilly acquired Ventryx a few months ago for its NLRP3 inhibitor. BIOA has the best one in class.
0 · Reply
NoKaOi
NoKaOi Mar. 23 at 2:49 PM
$BIOA might stay to tip toe back in. Seeing where this falls to.
0 · Reply
Bazzzigar
Bazzzigar Mar. 14 at 2:56 PM
$BIOA join with HIMS
0 · Reply
NoKaOi
NoKaOi Mar. 2 at 6:33 PM
$IBRX Sold 1000 of my $BIOA going to sit at $10.70
0 · Reply
NoKaOi
NoKaOi Mar. 2 at 10:59 AM
$BIOA in for 1000 shares at $20.25. Quietly watching.
0 · Reply